Baseline characteristics among the 3 cohorts
| Characteristic . | FMUSP (N = 167) . | FMRP (N = 145) . | OUH (N = 157) . | P* . |
|---|---|---|---|---|
| Age, median (IQR), y | 46.7 (32.9-57.3) | 43 (27-52) | 51.4 (42.4-59) | <.001 |
| Albumin, median (IQR), g/dL | 3.5 (3.1-4.0) | 3.7 (3.2-4.0) | 4.1 (3.9-4.4) | <.001 |
| WBC, median (IQR), ×103/μL | 16.9 (2.5-50.7) | 20.6 (6.0-55.9) | 12.4 (6.9-24.6) | .053 |
| Hemoglobin, median (IQR), g/dL | 7.9 (6.4-9.3) | 8.1 (7.0-9.2) | 10.2 (8.4-12.1) | <.001 |
| PLT, median (IQR), ×103/μL | 38.0 (24.0-76.0) | 53.0 (25.0-96.0) | 91.0 (52.5-211.5) | <.001 |
| BM blast, median (IQR), % | 62 (38-81) | 69 (42-87) | 55 (38-80) | .07 |
| LDH, normalized ratio, median (IQR) | 1.7 (1.0-2.9) | 1.8 (0.9-3.4) | 1.6 (1.0-3.0) | .77 |
| Sex, n (%) | ||||
| Female | 92 (55) | 78 (54) | 68 (43) | .07 |
| Male | 75 (45) | 67 (46) | 89 (57) | |
| Diagnosis, n (%) | ||||
| De novo AML | 155 (93) | 143 (98.5) | 137 (88) | <.001 |
| Secondary | 12 (7) | 2 (1.5) | 20 (12) | |
| Cytogenetics, n (%)† | ||||
| Favorable | 26 (17) | 31 (26) | 12 (11) | .03 |
| Intermediate | 97 (64) | 80 (61) | 76 (69) | |
| Adverse | 28 (19) | 16 (23) | 22 (20) | |
| Missing‡ | 16 (—) | 17 (—) | 47 (—) | |
| NPM1 mutation, n (%) | ||||
| Yes | 29 (21) | 19 (19) | 25 (25) | .49 |
| No | 111 (79) | 82 (81) | 73 (75) | |
| Missing‡ | 17 (—) | 44 (—) | 59 (—) | |
| CEBPa-biallelic mutation, n (%) | ||||
| Yes | 3 (3) | 2 (3) | 2 (2) | .91 |
| No | 95 (97) | 58 (97) | 88 (98) | |
| Missing‡ | 69 (—) | 76 (—) | 67 (—) | |
| FLT3-ITD mutation, n (%) | ||||
| Yes | 29 (19) | 36 (26) | 25 (26) | .24 |
| No | 125 (81) | 101 (74) | 71 (74) | |
| Missing‡ | 13 (—) | 8 (—) | 61 (-) | |
| AGR, n (%) | ||||
| Favorable | 44 (26.5) | 48 (34) | 28 (20.5) | .09 |
| Intermediate | 85 (51.5) | 58 (41.5) | 72 (52) | |
| Adverse | 36 (22) | 34 (24.5) | 38 (27.5) | |
| Missing‡ | 2 (—) | 5 (—) | 19 (—) | |
| Induction therapy, n (%)§ | ||||
| Anthracycline-based | 141 (84.5) | 140 (96.5) | 147 (96) | <.001 |
| Other | 26 (15.5) | 4 (3.5) | 6 (4) | |
| HSCT CR1, n (%) | ||||
| Yes | 23 (19.5) | 19 (19) | 88 (60.5) | <.001 |
| No | 96 (80.5) | 80 (82) | 57 (39.5) |
| Characteristic . | FMUSP (N = 167) . | FMRP (N = 145) . | OUH (N = 157) . | P* . |
|---|---|---|---|---|
| Age, median (IQR), y | 46.7 (32.9-57.3) | 43 (27-52) | 51.4 (42.4-59) | <.001 |
| Albumin, median (IQR), g/dL | 3.5 (3.1-4.0) | 3.7 (3.2-4.0) | 4.1 (3.9-4.4) | <.001 |
| WBC, median (IQR), ×103/μL | 16.9 (2.5-50.7) | 20.6 (6.0-55.9) | 12.4 (6.9-24.6) | .053 |
| Hemoglobin, median (IQR), g/dL | 7.9 (6.4-9.3) | 8.1 (7.0-9.2) | 10.2 (8.4-12.1) | <.001 |
| PLT, median (IQR), ×103/μL | 38.0 (24.0-76.0) | 53.0 (25.0-96.0) | 91.0 (52.5-211.5) | <.001 |
| BM blast, median (IQR), % | 62 (38-81) | 69 (42-87) | 55 (38-80) | .07 |
| LDH, normalized ratio, median (IQR) | 1.7 (1.0-2.9) | 1.8 (0.9-3.4) | 1.6 (1.0-3.0) | .77 |
| Sex, n (%) | ||||
| Female | 92 (55) | 78 (54) | 68 (43) | .07 |
| Male | 75 (45) | 67 (46) | 89 (57) | |
| Diagnosis, n (%) | ||||
| De novo AML | 155 (93) | 143 (98.5) | 137 (88) | <.001 |
| Secondary | 12 (7) | 2 (1.5) | 20 (12) | |
| Cytogenetics, n (%)† | ||||
| Favorable | 26 (17) | 31 (26) | 12 (11) | .03 |
| Intermediate | 97 (64) | 80 (61) | 76 (69) | |
| Adverse | 28 (19) | 16 (23) | 22 (20) | |
| Missing‡ | 16 (—) | 17 (—) | 47 (—) | |
| NPM1 mutation, n (%) | ||||
| Yes | 29 (21) | 19 (19) | 25 (25) | .49 |
| No | 111 (79) | 82 (81) | 73 (75) | |
| Missing‡ | 17 (—) | 44 (—) | 59 (—) | |
| CEBPa-biallelic mutation, n (%) | ||||
| Yes | 3 (3) | 2 (3) | 2 (2) | .91 |
| No | 95 (97) | 58 (97) | 88 (98) | |
| Missing‡ | 69 (—) | 76 (—) | 67 (—) | |
| FLT3-ITD mutation, n (%) | ||||
| Yes | 29 (19) | 36 (26) | 25 (26) | .24 |
| No | 125 (81) | 101 (74) | 71 (74) | |
| Missing‡ | 13 (—) | 8 (—) | 61 (-) | |
| AGR, n (%) | ||||
| Favorable | 44 (26.5) | 48 (34) | 28 (20.5) | .09 |
| Intermediate | 85 (51.5) | 58 (41.5) | 72 (52) | |
| Adverse | 36 (22) | 34 (24.5) | 38 (27.5) | |
| Missing‡ | 2 (—) | 5 (—) | 19 (—) | |
| Induction therapy, n (%)§ | ||||
| Anthracycline-based | 141 (84.5) | 140 (96.5) | 147 (96) | <.001 |
| Other | 26 (15.5) | 4 (3.5) | 6 (4) | |
| HSCT CR1, n (%) | ||||
| Yes | 23 (19.5) | 19 (19) | 88 (60.5) | <.001 |
| No | 96 (80.5) | 80 (82) | 57 (39.5) |
BM, bone marrow; HGB, hemoglobin; IQR, interquartile range; LDH, lactic dehydrogenase; PLT, platelets; USL, upper superior limit.
P value: Kruskal-Wallis and χ2/Fisher's exact tests for intercohort comparisons.
MRC cytogenetic risk.22
Missing data are being considered neither for groups proportions nor for P value calculation.
Anthracycline-based: any regimen containing anthracycline in combination with other agents. Other: regimens not containing anthracycline in their composition (supplemental Table 7).